Shearit

Shearit LLC is a biotechnology company focused on developing a novel treatment for cerebrovascular diseases like acute ischemic stroke. The company was founded in 2019 by Dr. Edwin Nemoto, who serves as the CEO. Dr. Nemoto's research, which began upon his arrival at the University of New Mexico in 2009, led to the development of Lamiflo™, an injectable high molecular weight polymer.

The core of Shearit's work is Lamiflo™, a patented compound designed to improve blood flow by altering its physical dynamics rather than through pharmacological means. This technology is considered disruptive because it can be administered in the pre-hospital phase of a stroke, potentially increasing the number of patients eligible for existing treatments like thrombolysis or intra-arterial thrombectomy. It may also be used for patients who do not qualify for these standard procedures.

The company's business model revolves around bringing Lamiflo™ through clinical trials to eventual commercialization. Shearit was recently awarded a $490,049 Phase I SBIR grant from the National Institutes of Health (NIH) to conduct proof-of-concept research on Lamiflo's effectiveness in extending the ischemic penumbra in large vessel occlusion strokes. The company operates with a small team and is privately held, with its main office in Albuquerque, New Mexico. The leadership team includes experienced professionals such as Dr. Howard Yonas (Chief Medical Officer), Steve Wiley (COO), and Mike Renn (President).

Keywords: cerebrovascular disease, acute ischemic stroke, Lamiflo, neuroprotective treatment, injectable polymer, blood flow dynamics, pre-hospital stroke care, thrombolysis, thrombectomy, biotechnology, clinical trials, NIH grant, Edwin Nemoto, large vessel occlusion, ischemic penumbra